Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Immunome reported a net loss of $57.5 million for the third quarter ended September 30, 2025, compared to $47.1 million in the same period last year135.

Basic and diluted loss per share from continuing operations for Q3 2025 was $0.65, an improvement from $0.78 a year ago1.

Cash and cash equivalents totaled $272.6 million as of September 30, 2025, including $44.9 million raised through at-the-market equity transactions; this is expected to fund operations into 20273.

Research and development expenses for the quarter were $49.2 million (including $2.9 million stock-based compensation), and general and administrative expenses were $10.9 million ($3.9 million in stock-based compensation)3.

Immunome highlighted progress in its pipeline:
topline data readout for the Phase 3 RINGSIDE trial of varegacestat is anticipated before the end of 2025, with a potential NDA submission to follow3.

Early clinical activity was observed in B-cell lymphoma patients treated with IM-1021, underscoring the potential of their proprietary TOP1 inhibitor ADC payload (HC74). Initial full data for this program is planned for 20263.

Other pipeline assets include IM-3050 (a FAP-targeted radioligand recently cleared for IND), and several preclinical ADC programs (IM-1617, IM-1335, IM-1340) targeting various solid tumors3.

Immunome remains committed to advancing first-in-class and best-in-class targeted cancer therapies, leveraging experienced leadership in targeted oncology and ADCs3.

Sources:

1. https://www.marketscreener.com/news/immunome-inc-reports-earnings-results-for-the-third-quarter-and-nine-months-ended-september-30-20-ce7d5cd3df8cf421

3. https://www.businesswire.com/news/home/20251106467522/en/Immunome-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update

5. https://finimize.com/content/immunome-stays-confident-despite-heavy-losses-and-bold-spending